Literature DB >> 16354976

Intravenous immunoglobulins without initial and follow-up cordocentesis in alloimmune fetal and neonatal thrombocytopenia at high risk for intracranial hemorrhage.

Humphrey H H Kanhai1, Eline S A van den Akker, Frans J Walther, Anneke Brand.   

Abstract

OBJECTIVE: To report on a less invasive treatment strategy in alloimmune fetal and neonatal thrombocytopenia (FNAIT) at high risk for either in utero or neonatal intracranial hemorrhage (ICH).
METHODS: In 7 pregnancies, with a history of ICH in the older sibling, weekly intravenous immunoglobulin (IVIG) therapy to the mother (1 g/kg) without initial cordocentesis was started at a median gestational age of 16 weeks.
RESULTS: In 4 pregnancies cordocentesis was avoided. One predelivery cordocentesis with platelet transfusion was performed in 3 further cases. Although none of the cases had a platelet count of >50 x 10(9)/l at cordocentesis, predelivery or birth, no ICHs were observed. The neonatal periods of the infants were uncomplicated.
CONCLUSION: IVIG treatment alone might be considered in patients with both severe platelet alloimmunization and an increased risk for morbidity and mortality at cordocentesis. (c) 2006 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16354976     DOI: 10.1159/000089048

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  4 in total

1.  Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.

Authors:  D J Jackson; J L Eastlake; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

2.  Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.

Authors:  Cedric Ghevaert; David A Wilcox; Juan Fang; Kathryn L Armour; Mike R Clark; Willem H Ouwehand; Lorna M Williamson
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

3.  Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.

Authors:  Huiying Zhi; Maria T Ahlen; Björn Skogen; Debra K Newman; Peter J Newman
Journal:  Blood Adv       Date:  2021-09-28

4.  Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia.

Authors:  Ying-Jan Weng; Anne Husebekk; Björn Skogen; Mette Kjaer; Liang-Tzung Lin; Thierry Burnouf
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.